Abemaciclib
APC-1765
Abemaciclib
Cat. No.
APC-1765
CAS No.
1231929-97-7
MF
C27H32F2N8
MW
506.59
Abemaciclib is a selective and BBB-permeable CDK4/6 inhibitor.
Technical Service Need help? Our team of experienced experts is here for you with full support.
86-28-85159085
info@aktin.com
Technical Data
Description
Storage and Shipping
References
Product Name
CAS No.
1231929-97-7
MF
C27H32F2N8
MW
506.59
Specification
98%
Research Area
a selective and BBB-permeable CDK4/6 inhibitor
Description
Abemaciclib is a selective and BBB-permeable CDK4/6 inhibitor. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g Availability: In stock
Documents
Certificate of Analysis (COA), Specification Sheet, HPLC, 1HNMR, 13CNMR, IR, MS, Safety Data Sheet (SDS/MSDS) etc.
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7(12):14803-13.
[2]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.
[3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37.
[4]. Solmaz Sahebjam et al. Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer. J Clin Oncol 34. 2016, 526-526.
[2]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.
[3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37.
[4]. Solmaz Sahebjam et al. Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer. J Clin Oncol 34. 2016, 526-526.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
APC-1826
AkVEri® Isoalantolactone R-2
CAS No.:3115310-00-1
MF:C18H29NO5
APC-1825
AkVEri® Isoalantolactone R-1
CAS No.:3115309-99-1
MF: C19H31NO5
APC-1824
(Z)-Dimethylvinphos
CAS No.:67628-93-7
MF:C10H10Cl3O4P
APC-1808
Fusicoccin from Fusicoccum amygdali
CAS No.:20108-30-9
MF:C36H56O12
APC-1807
Ethylene-d4-diamine dihydrochloride
CAS No.:34334-71-9
MF:C2H4D4N2.2ClH
APC-1791
Uniconazole P
CAS No.:83657-17-4
MF:C15H18ClN3O
APC-1782
Fluoranthene-d10
CAS No.:93951-69-0
MF:C16D10
APC-1772
Melibiose
CAS No.:585-99-9
MF:C12H22O11
APC-1771
Mannan (ex Saccharomyces cerevisiae)
CAS No.:9036-88-8
MF:C24H42O21
APC-1768
Isosorbide 2-mononitrate
CAS No.:16106-20-0
MF:C6H9NO6
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
